MIRM

Mirum Pharmaceuticals Inc

MIRM, USA

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

https://www.mirumpharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MIRM
stock
MIRM

Baird lifts Mirum Pharmaceuticals, Inc. (MIRM) price target on Bluejay Therapeutics acquisition MSN

Read more →
MIRM
stock
MIRM

Baird Lifts Mirum Pharmaceuticals, Inc. (MIRM) Price Target on Bluejay Therapeutics Acquisition Insider Monkey

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$87.994

Analyst Picks

Strong Buy

6

Buy

4

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

12.68

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

0.99 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

0.37 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

29.69 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.69

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 93.33% of the total shares of Mirum Pharmaceuticals Inc

1.

HHG PLC

(10.423%)

since

2025/06/30

2.

BlackRock Inc

(7.1203%)

since

2025/06/30

3.

Bvf Inc

(5.4965%)

since

2025/06/30

4.

Eventide Asset Management, LLC

(5.25%)

since

2025/06/30

5.

Vanguard Group Inc

(5.1055%)

since

2025/06/30

6.

Novo A/S

(2.9859%)

since

2025/06/30

7.

Eventide Gilead N

(2.8472%)

since

2025/06/30

8.

T. Rowe Price Associates, Inc.

(2.821%)

since

2025/06/30

9.

Citadel Advisors Llc

(2.7994%)

since

2025/06/30

10.

State Street Corp

(2.7382%)

since

2025/06/30

11.

Vanguard Total Stock Mkt Idx Inv

(2.6662%)

since

2025/07/31

12.

TANG CAPITAL MANAGEMENT LLC

(2.4604%)

since

2025/06/30

13.

Eventide Healthcare & Life Sciences I

(2.3778%)

since

2025/06/30

14.

iShares Russell 2000 ETF

(2.0837%)

since

2025/08/31

15.

Geode Capital Management, LLC

(2.0495%)

since

2025/06/30

16.

ClearBridge Advisors, LLC

(2.0453%)

since

2025/06/30

17.

Polar Capital Holdings PLC

(1.9408%)

since

2025/06/30

18.

Polar Capital Biotech S Inc

(1.9408%)

since

2025/07/31

19.

Rock Springs Capital Management LP

(1.6287%)

since

2025/06/30

20.

Janus Henderson Global Life Sciences D

(1.5427%)

since

2025/06/30

21.

Janus Henderson Global Life Sciences

(1.5427%)

since

2025/06/30

22.

Lord, Abbett & Co LLC

(1.535%)

since

2025/06/30

23.

US Small-Cap Growth II Equity Comp

(1.4257%)

since

2025/06/30

24.

ClearBridge Small Cap Growth A

(1.4069%)

since

2025/07/31

25.

Pictet Asset Manangement SA

(1.3957%)

since

2025/06/30

26.

ClearBridge Small Cap Growth

(1.3916%)

since

2025/07/31

27.

Janus Henderson Triton D

(1.3518%)

since

2025/06/30

28.

Janus Henderson US SMID Cap Growth

(1.3518%)

since

2025/06/30

29.

Janus Henderson US SMID Cap Growth MA

(1.3518%)

since

2025/06/30

30.

BOONE CAPITAL MANAGEMENT LLC

(1.2768%)

since

2025/06/30

31.

Janus Global Life Science AUSD

(1.2765%)

since

2025/06/30

32.

Janus Henderson Glb Life Scn I2 USD

(1.2643%)

since

2025/07/31

33.

T. Rowe Price New Horizons

(1.249%)

since

2025/07/31

34.

Franklin Resources Inc

(1.1816%)

since

2025/06/30

35.

Nuveen, LLC

(1.1749%)

since

2025/06/30

36.

Woodline Partners LP

(1.1304%)

since

2025/06/30

37.

Janus Henderson Venture D

(0.9571%)

since

2025/06/30

38.

Janus Henderson US Small Cap Growth

(0.9571%)

since

2025/06/30

39.

SPDR® S&P Biotech ETF

(0.9023%)

since

2025/08/31

40.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8886%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.1331

Latest Release

Date

2025-09-30

EPS Actual

0.05

EPS Estimate

-0.15

EPS Difference

0.2

Surprise Percent

133.3333%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(5.5)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.